Combined Shareholders’ Meeting of Ipsen S.A. Held on 24 May 2022

·2 min read

ALL THE RESOLUTIONS SUBMITTED TO THE SHAREHOLDERS’ VOTE HAVE BEEN APPROVED.

BOULOGNE-BILLANCOURT, France, May 24, 2022--(BUSINESS WIRE)--Regulatory News:

The Combined Shareholders’ Meeting of Ipsen S.A. (Euronext: IPN; ADR: IPSEY), was held today at the Salons de l'Hôtel des Arts et Métiers, 9 bis, avenue d'Iéna, 75116 Paris (France), under the chairmanship of Mr. Marc de GARIDEL, Chairman of the Board of Directors of Ipsen and meeting Chairman, and in the presence of the members of the Board of Directors and the Group’s Executive Leadership Team.

The Shareholders’ Meeting approved all of the 20 resolutions submitted by the Board of Directors and in particular the payment of a dividend of €1.20 per share. This dividend will be paid on 2 June 2022, the ex-date being 31 May 2022.

The Meeting also approved the appointment of PricewaterhouseCoopers Audit as Statutory auditor in replacement of Deloitte & Associés and the renewal of the terms of office of the company Highrock S.àr.l. and of Mr. Paul SEKHRI and Mr. Piet WIGERINCK for a duration of four years, as directors. It additionally ratified the temporary appointment as a director of Mrs Karen WITTS.

During the Meeting, Mr. David LOEW, Chief Executive Officer, and Mr. Aymeric Le CHATELIER, Group Chief Financial Officer, focused notably on the group strategy, the 2021 financial performance, the financial objectives for the year 2022.

Ipsen

Ipsen is a global, mid-sized biopharmaceutical company focused on transformative medicines in Oncology, Rare Disease and Neuroscience. With Specialty Care sales of €2.6bn in FY 2021, Ipsen sells medicines in over 100 countries. Alongside its external-innovation strategy, the Company’s research and development efforts are focused on its innovative and differentiated technological platforms located in the heart of leading biotechnological and life-science hubs: Paris-Saclay, France; Oxford, U.K.; Cambridge, U.S.; Shanghai, China. Ipsen, excluding its Consumer HealthCare business, has around 4,500 colleagues worldwide and is listed in Paris (Euronext: IPN) and in the U.S. through a Sponsored Level I American Depositary Receipt program (ADR: IPSEY). For more information, visit ipsen.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220524006016/en/

Contacts

Ipsen S.A.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting